Celgene (Bristol-Myers Squibb)

Celgene was a biotechnology company specializing in developing therapies for cancer and inflammatory diseases. It was known for its focus on innovative drug discovery, notably its cancer treatment Revlimid. In 2019, Bristol-Myers Squibb acquired Celgene to enhance its portfolio of medicines, especially in immunology and oncology. This acquisition expanded Bristol-Myers Squibb’s capabilities in developing advanced therapies for serious diseases, making it a major player in the pharmaceutical industry.